Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F14%3A10283005" target="_blank" >RIV/00216208:11150/14:10283005 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1038/leu.2014.2" target="_blank" >http://dx.doi.org/10.1038/leu.2014.2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/leu.2014.2" target="_blank" >10.1038/leu.2014.2</a>

Result language
angličtina
Original language name
Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
Original language description
The inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple myeloma (MM) by using a Smac (secondmitochondria-derived activator of caspases)-mimetic LCL161. We observed that LCL161 was able to potently induce apoptosis in some MM cell lines but not in others. Examining the levels of X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitorof apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2) post LCL161 treatment indicated clear downregulation of both XIAP activity and clAP1 levels in both the sensitive and less sensitive (resistant) cell lines. clAP2, however, was not downregulated in the cell line resistant to the drug. Small interfering RNA-mediated silencing of clAP2 significantly enhanced the effect of LCL161, indicating the importance of downregulation of all IAPs simultaneously for i
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)